» Articles » PMID: 40066790

Rapid Development of Unclassified Myeloid Lineage Acute Leukaemia With Trisomy 6 and U2AF1 Mutation

Abstract

We present a case of acute clonal bone marrow 98% infiltration of atypical myeloid cells with borderline hypogranular/agranular promyelocytes/myelocytes and occasional blast cells maturity, which also formed extramedullary tumours in the chest wall, with isolated trisomy of chromosome 6 and pathogenic variant U2AF1 (S34F) that escapes established acute myeloid leukaemia (AML) diagnostic criteria according to the World Health Organization (WHO) classification. Following standard daunorubicin and cytarabine induction therapy, the disease progressed with the appearance of a previously undetected clone of leukaemic cells with a distinct immunophenotype demonstrating monocytoid differentiation and clonal evolution to a hypo-tetraploid karyotype with an average number of 84 chromosomes and new pathogenic NRAS and ZRSR2 mutations. The patient reactivated refractory disseminated intravascular coagulation (DIC) leading to a progressive supratentorial hematoma and finally cardiac arrest. In conclusion, our report shows that atypical clonal myelocytes can massively infiltrate the bone marrow and form extramedullary tumours, justifying the diagnosis and treatment of acute leukaemia, although they did not fit the current classification.

References
1.
Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

2.
Awada H, Durmaz A, Kewan T, Ullah F, Dima D, Awada H . Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis. Leukemia. 2024; 38(6):1411-1414. PMC: 11147751. DOI: 10.1038/s41375-024-02268-w. View

3.
Badar T, Vanegas Y, Nanaa A, Foran J, Al-Kali A, Mangaonkar A . U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer J. 2023; 13(1):149. PMC: 10514309. DOI: 10.1038/s41408-023-00922-7. View

4.
Geoffroy M, Esnault C, de The H . Retinoids in hematology: a timely revival?. Blood. 2021; 137(18):2429-2437. DOI: 10.1182/blood.2020010100. View

5.
Alawieh D, Cysique-Foinlan L, Willekens C, Renneville A . RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J. 2024; 14(1):72. PMC: 11043080. DOI: 10.1038/s41408-024-01054-2. View